Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02049957
Title Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer
Recruitment Completed
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.

estrogen-receptor positive breast cancer

Her2-receptor negative breast cancer


Fulvestrant + Sapanisertib

Exemestane + Sapanisertib

Age Groups: adult
Covered Countries USA | FRA | BEL

No variant requirements are available.